ReviewOxidative medicine and cellular longevity2021
Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury.
Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- The core role of central nervous system in sepsis-related organ damage.Frontiers in immunology · 2025Pooled it
- Research progress of ferroptosis in gynecological diseases.Annals of medicine · 2026Review
- Inhibition of Dyrk1a attenuates type 1 diabetic cardiomyopathy via anti‑ferroptosis.Molecular medicine reports · 2026Article
- Heparin-Binding Protein and Transplant-Associated Inflammation: Emerging Roles in Infection, Ischemia-Reperfusion Injury, and Allograft Dysfunction.Journal of clinical medicine · 2026Review
- Clinical implications of ferroptosis in critical illness: a narrative review.Journal of intensive care · 2026Review
- Temporal changes of oxidative stress and ferroptosis-associated biomarkers in STEMI patients undergoing primary PCI and their correlation with myocardial reperfusion injury.BMC cardiovascular disorders · 2026Article
- ETV4 Improves Cerebral Ischemia-Reperfusion Injury by Restraining YBX1-GPX4-Ferroptosis Cascades.Brain and behavior · 2026Article
- Research Progress on the Role of Traditional Chinese Medicine in Regulating Ferroptosis in Cardiovascular Diseases.Biology · 2026Review
- Nrf2/SLC7A11/GPX4 pathway, a potential target of oridonin in inhibiting ferroptosis during cerebral ischemia-reperfusion injury progression.Scientific reports · 2026Article
- ENPP2 Protects Mouse Myocardium from Ischemia-Reperfusion-Induced Ferroptosis Injury Via the SIRT1/PGC-1α/NRF1 Pathway.Applied biochemistry and biotechnology · 2026Article
- Lactylation‑mediated ferroptosis: A novel mechanism and therapeutic prospects in human diseases (Review).International journal of molecular medicine · 2026Review
- HIF-1α/BNIP3-mediated mitophagy mitigates cerebral ischemia/reperfusion injury in rats by suppressing NLRP3 inflammasome activation.European journal of medical research · 2026Article
- [Protective effects of SESN2 on Erastin-induced ferroptosis in renal tubular cells and acute kidney injury].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Macrophage ferroptosis in hematologic malignancies: emerging mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026Review
- Heterogeneity of Microglia in Ischemic Stroke from the Perspective of Single-Cell RNA Sequencing: Subset Characteristics, Mechanisms and Therapeutic Potential.Journal of central nervous system disease · 2026Review
- Salvianic Acid A Regulates Ferroptosis by Activating the Nrf2-GPX4 Pathway Through EGFR to Protect Myocardial Ischemia-Reperfusion Injury.Journal of inflammation research · 2026Article
- Predictive value of Index of Cardiac Electrophysiological Balance (ICEB) for ischemia-reperfusion injury following coronary artery angioplasty.American journal of translational research · 2026Article
- Modelling Ferroptosis in a Human Microglial Line by Sequential Exposure to Iron and GPX4 Inhibition.Oxidative medicine and cellular longevity · 2026Article
- Ferroptosis in Ischemic Stroke: Insights from Natural Product Treatment and Future Directions.Drug design, development and therapy · 2026Review
- Protective Role and Mechanism of Action of Garlic in Organ Ischemia-reperfusion Injury: Where do we Stand?Current medicinal chemistry · 2026Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion (I/R) is a pathological process that occurs in many organs and diseases. Reperfusion, recovery of blood flow, and reoxygenation often lead to reperfusion injury. Drug therapy and early reperfusion therapy can reduce tissue injury and cell necrosis caused by ischemia, leading to irreversible I/R injury. Ferroptosis was clearly defined in 2012 as a newly discovered iron-dependent, peroxide-driven, nonapoptotic form of regulated cell death. Ferroptosis is considered the cause of reperfusion injury. This discovery provides new avenues for the recognition and treatment of diseases. Ferroptosis is a key factor that leads to I/R injury and organ failure. Given the important role of ferroptosis in I/R injury, there is considerable interest in the potential role of ferroptosis as a targeted treatment for a wide range of I/R injury-related diseases. Recently, substantial progress has been made in applying ferroptosis to I/R injury in various organs and diseases. The development of ferroptosis regulators is expected to provide new opportunities for the treatment of I/R injury. Herein, we analytically review the pathological mechanism and targeted treatment of ferroptosis in I/R and related diseases from the perspectives of myocardial I/R injury, cerebral I/R injury, and ischemic renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.